Regeneron Narrows Bids to Block Eylea Biosimilars to One Patent

Regeneron Pharmaceuticals Inc. will lean on just one of the dozens of patents behind its Eylea biologic as it seeks to block three drugmakers from selling biosimilar versions of the blockbuster drug while their infringement lawsuits continue, the company told a West Virginia federal judge.

Regeneron—which attributed nearly 44% of its 2023 revenue to Eylea’s US sales—said it wants to “streamline the issues” by withdrawing its bids for preliminary injunctions against Samsung Bioepis Co., Celltrion Inc., and Formycon AG with respect to all but US Patent No. 11,084,865, according to a motion filed Tuesday in the US District ...